Table 2 Treatments before Axitinib
From: Axitinib as a third or further line of treatment in renal cancer: a single institution experience
|  | 1st line (n = 22) | 2nd line (n = 22) | 3rd line (n = 10) | 4th line (n = 6) | 5th line (n = 3) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
Agent(s) | n | % | n | % | n | % | n | % | n | % |
Sunitinib | 14 | 63.6 | 0 | 0 | 1 | 10 | 0 | 0 | 0 | 0 |
Pazopanib | 3 | 13.6 | 3 | 13.6 | 1 | 10 | 4 | 66.6 | 1 | 33.3 |
Sunitinib- Everolimus (Sequential) | 4 | 18.2 | 4 | 18.2 | 0 | 0 | 0 | 0 | 0 | 0 |
Bevacizumab | 1 | 4.5 | 0 | 0 | 1 | 10 | 0 | 0 | 0 | 0 |
Temsirolimus- Bevacizumab (Concurrent) | 0 | 0 | 2 | 9 | 0 | 0 | 0 | 0 | 0 | 0 |
Nivolumab | 0 | 0 | 1 | 4.5 | 1 | 10 | 0 | 0 | 0 | 0 |
Sorafenib | 0 | 0 | 1 | 4.5 | 3 | 30 | 0 | 0 | 0 | 0 |
Dovitinib | 0 | 0 | 0 | 0 | 1 | 10 | 0 | 0 | 0 | 0 |
Everolimus | 0 | 0 | 11 | 50 | 2 | 20 | 2 | 33.3 | 0 | 0 |
Temsirolimus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 66.6 |
Total | 22 | 100 | 22 | 100 | 10 | 100 | 6 | 100 | 3 | 100 |